Histological characterization of liver involvement in systemic mastocytosis

Author:

Rossignol Julien1ORCID,Canioni Danielle2,Aouba Achille3,Bulai‐Livideanu Cristina4,Barete Stéphane5,Lancesseur Charles6,Polivka Laura1,Madrange Marine1,Ballul Thomas1,Neuraz Antoine7,Greco Celine1,Agopian Julie89,Brenet Fabienne89,Dubreuil Patrice89,Lemal Richard10ORCID,Tournilhac Olivier11,Terriou Louis12,Launay David1213,Bouillet Laurence14,Gourguechon Clément15,Frenzel Laurent1,Meni Cécile1,Gaudy‐Marqueste Caroline16,Gousseff Marie17,Le Mouel Edwige18,Hamidou Mohamed19,Neel Antoine19,Ranta Dana20,Jaussaud Roland21,Guilpain Philippe22,Molina Thierry J2,Bruneau Julie2,Lhermitte Ludovic23,Garcelon Nicolas24,Javier Rose‐Marie25,Pelletier Fabien26,Castelain Florence26,Retornaz Frederique27,Cabrera Quentin28,Zunic Patricia28,Gourin Marie Pierre29,Wierzbicka‐Hainaut Ewa30,Viallard Jean François31,Lavigne Christian32,Hoarau Cyrille33,Durieu Isabelle34,Heiblig Maël35,Dimicoli‐Salazar Sophie36,Torregrosa‐Diaz Jose M37,Soria Angèle38,Arock Michel39,Lortholary Olivier140,Bodemer Christine1,Pol Stanislas41,Mallet Vincent41ORCID,Hermine Olivier1,Damaj Ghandi6,

Affiliation:

1. CEREMAST, Imagine Institute, INSERM U1163, AP‐HP, Necker Children's Hospital, Paris Centre University Paris France

2. CEREMAST, Department of Pathology Necker Children's Hospital, AP‐HP, Paris Centre University Paris France

3. Department of Internal Medicine Normandy University School of Medicine Caen France

4. CEREMAST, Department of Dermatology Hôpital Larrey, CHU Toulouse Toulouse France

5. CEREMAST, Dermatology Department Pitié‐Salpêtrière Hospital, AP‐HP Paris France

6. CEREMAST Hematology Institute, Normandy University School of Medicine Caen France

7. Department of Bioinformatics Necker Children's Hospital, AP‐HP, Paris Centre University, Imagine Institute, INSERM U1163 Paris France

8. Centre de Recherche en Cancérologie de Marseille INSERM U1068 Marseille France

9. Association Française pour les Initiatives de Recherche sur le Mastocyte et les Mastocytoses (AFIRMM) Marseille France

10. Histocompatibility Laboratory EA 7453—Université Clermont Auvergne, CHU de Clermont‐Ferrand Clermont‐Ferrand France

11. CEREMAST, Adult Clinical Hematology CHU Clermont‐Ferrand, INSERM CIC501, EA 7453 – Clermont Auvergne University Clermont‐Ferrand France

12. CEREMAST, Department of Internal Medicine and Clinical Immunology CHU Lille Lille France

13. Lille University, INSERM U1286 INFINITE, CHU Lille Lille France

14. CEREMAST, Clinical Immunology/Internal Medicine Department, National Reference Center for Angioedema Grenoble University Hospital Grenoble France

15. Department of Hematology Amiens University Hospital Amiens France

16. CEREMAST, Department of Dermatology Aix‐Marseille University, CHU Timone Marseille France

17. Department of Internal Medicine Centre Hospitalier Bretagne Atlantique Vannes France

18. CEREMAST, Department of Internal Medicine and Clinical Immunology Rennes University Hospital Rennes France

19. CEREMAST, Department of Internal Medicine Hôtel‐Dieu University Hospital Nantes France

20. Department of Hematology Nancy University Hospital Nancy France

21. Department of Internal Medicine and Clinical Immunology Nancy University Hospital Vandoeuvre‐lès‐Nancy France

22. CEREMAST, Department of Internal Medicine‐Multi‐organ Diseases Saint‐Eloi University Hospital, Montpellier University Montpellier France

23. CEREMAST, Laboratory of Onco‐Hematology Necker Children's Hospital, APHP Paris France

24. Paris Centre University, Imagine Institute, Data Science Platform, INSERM UMR 1163 Paris France

25. CEREMAST, Department of Rheumatology Strasbourg University Hospital Strasbourg France

26. CEREMAST, Department of Dermatology, Allergology Unit University Hospital of Besançon Besançon France

27. Unité de soins et de recherche en médecine interne et maladies infectieuses European Hospital Marseille France

28. Department of Haematology Sud Reunion University Hospital Saint Pierre La Réunion France

29. CEREMAST, Department of Hematology CHU Dupuytren Limoges France

30. CEREMAST, Department of Dermatology CHU de Poitiers Poitiers France

31. Department of Internal Medicine and Infectious Diseases Haut‐Lévêque Hospital, CHRU Bordeaux, Bordeaux University Bordeaux France

32. CEREMAST, Department of Internal Medicine and Clinical Immunology University Hospital Angers France

33. CEREMAST, Service d'Immunologie Clinique et d'Allergologie Centre Hospitalier Régional Universitaire Tours France

34. CEREMAST, Department of Internal Medicine, Adult Cystic Fibrosis Care Center Hospices Civils de Lyon Lyon France

35. CEREMAST, Department of Hematology Lyon‐Sud Hospital, Hospices Civils de Lyon Pierre‐Bénite France

36. Department of Hematology CHU de Bordeaux Bordeaux France

37. Department of Hematology CHU de Poitiers Poitiers France

38. CEREMAST, Department of Dermatology and Allergy, Tenon Hospital Sorbonne University Paris France

39. CEREMAST, Laboratory of Hematology Pitié‐Salpêtrière Hospital, AP‐HP Paris France

40. Infectious and Tropical Diseases Department, Necker‐Pasteur Infectiology Center AP‐HP, Necker Children's Hospital, Paris Centre University Paris France

41. AP‐HP.Centre Université Paris Centre Groupe Hospitalier Cochin Port Royal, DMU Cancérologie et spécialités médico‐chirurgicales, Service d'Hépatologie Paris France

Abstract

AbstractBackground and AimsSystemic mastocytosis (SM) is characterized by the accumulation of atypical mast cells (MCs) in organs. Liver histology of SM has been marginally described and accurate histological classification is critical, given the consequences of aggressive SM diagnosis. We aimed to describe the histological features associated with liver SM using updated tools.MethodsUsing the database of the French Reference Centre for Mastocytosis, we retrospectively identified patients with a liver biopsy (LB) and a diagnosis of SM. All LB procedures were performed according to the local physician in charge and centrally reviewed by an expert pathologist.ResultsA total of 28 patients were included: 6 had indolent SM, 9 had aggressive SM, and 13 had SM with an associated hematologic neoplasm. Twenty‐five (89%) patients presented hepatomegaly, and 19 (68%) had portal hypertension. The LB frequently showed slight sinusoid dilatation (82%). Fibrosis was observed in 3/6 indolent SM and in almost all advanced SM cases (21/22), but none of them showed cirrhosis. A high MC burden (>50 MCs/high‐power field) was correlated with elevated blood alkaline phosphatase levels (p = .030). The presence of portal hypertension was associated with a higher mean fibrosis grade (1.6 vs. 0.8 in its absence; p = .026). In advanced SM, the presence of nodular regenerative hyperplasia (NRH) was associated with decreased overall survival (9.5 vs. 46.3 months, p = .002).ConclusionsMC infiltration induced polymorphic hepatic lesions and the degree of fibrosis is associated with portal hypertension. NRH identifies a poor prognosis subgroup of patients with advanced SM. Assessing liver histology can aid in SM prognostic evaluation.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3